CDR grafted anti-CEA antibodies and their production
US5877293A · kind A · utility
231Cited by
1References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 24, 1995 |
| Grant date | Mar 2, 1999 |
| Priority date | — |
| Expiry date | May 24, 2015 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/035
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides humanized antibody molecules (HAMs) having specificity for carcinoembryonic antigen (CEA) and having an antigen binding site wherein at least one of the complementarity determining regions (CDRs) of the variable domains is derived from the mouse monoclonal antibody A5B7 (A5B7 MAB) and the remaining immunoglobulin-derived parts of the HAM are derived from a human immunoglobulin. The HAMs may be chimeric humanized antibodies or CDR-grafted humanized antibodies and are preferably produced by recombinant DNA techniques. The HAMs are useful for in vivo diagnosis and therapy.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.